[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514078":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":27,"locations":37,"responsibleParty":53,"collaborators":23,"id":57,"slug":23,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":23,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":23,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":39,"whyStopped":23,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Cincinnati","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fasting","EXPERIMENTAL","Subjects will remain fasted prior to insulin-induced hypoglycemia.",[13],"Other: Fasting",{"label":15,"type":10,"description":16,"interventionNames":17},"Feeding","Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.",[18],"Other: Feeding",[20,24],{"type":6,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"Subjects remain fasted prior to insulin-induced hypoglycemia.",[9],null,{"type":6,"name":15,"description":25,"armGroupLabels":26,"otherNames":23},"Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.",[15],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Jason Winnick, PhD","CONTACT","513-558-4437","jason.winnick@uc.edu",{"name":34,"role":30,"phone":35,"phoneExt":23,"email":36},"Alyssa Randolph","513-558-3427","Randolas@ucmail.uc.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Cincinnati","Ohio","45267-0547","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-84.51439,39.12711,{"lat":49,"lon":48},[52],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"PRINCIPAL_INVESTIGATOR","Jason Winnick","Principal Investigator","100514078",false,"NCT05973799","Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes","Inclusion Criteria:\n\n* males and females of any race or ethnicity\n* non-obese (BMI \\\u003C or = to 30)\n* have a diagnosis of type 1 diabetes\n* C-peptide negative\n\nExclusion Criteria:\n\n* pregnant women\n* cigarette smoking\n* Taking inflammation-targeting steroids (e.g., prednisone).\n* Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).\n* Hematocrit less than 33%.\n* Presence of HIV or hepatitis (due to their deleterious effects on the liver).\n* The presence of cardiovascular or peripheral vascular disease.\n* The presence of neuropathy, retinopathy or nephropathy.\n* A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.","ALL","18 Years","45 Years",{"count":66,"type":67},10,"ESTIMATED","INTERVENTIONAL",[70],"NA","Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without diabetes that fasting can be detrimental to the hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, the impact fasting has on hypoglycemic counterregulation in people with T1D will be determined.",[73,74],"Hypoglycemia","Type1diabetes",[76,77,78],"glucagon","hepatic glucose metabolism","liver glycogen","2024-08-29",{"date":81,"type":82},"2024-09-03","ACTUAL",{"date":84,"type":82},"2019-10-10",{"date":86,"type":67},"2024-12-31",{"name":5,"class":6},1]